Resistance and sensitivity maps at residue resolution.
Compound–Target Assay uses geneSlice-powered saturation mutagenesis to map drug binding, drug response, and resistance pathways.
Compound–Target Assay uses geneSlice-powered saturation mutagenesis to identify which amino acid residues of your drug target matter for compound binding, drug response, and acquired resistance. The result is a residue-level map that informs medicinal chemistry optimisation and anticipates resistance pathways before they emerge in patients.
Four questions, one assay
- Which residues of my target are essential for compound binding?
- Which substitutions could block drug binding, or drive constitutive activation?
- Where should we focus medicinal chemistry optimisation to make compounds harder to escape?
- What resistance signatures should we expect, and how can we counter them with combinations?
Saturation mutagenesis with a matched readout.
We perform saturation mutagenesis across the region of your drug target you want to interrogate — typically the binding pocket or full functional domain. Using geneSlice, we generate a cell library in which each cell carries a different substitution of the target, then screen the library against your compound using a cell-based reporter assay.
A common architecture leverages synthetic lethality — a cell line that depends on the drug target for survival, so loss-of-function and resistance variants score directly through cell viability — but the readout is matched to the question.
What you receive
- Residue-level functional scores for every variant tested.
- Resistance and sensitivity heatmaps along the protein sequence.
- Structural mapping onto the target's 3D structure, where structural data is available.
- Raw data and analysis reports.
Standard geneSlice pipeline
Typically 6–12 months end-to-end, following the standard geneSlice project pipeline. See Technology.